Lexicon announces publication on cost-effectiveness of INPEFA

Lexicon Pharmaceuticals,announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. The analysis was conducted from a U.S. healthcare sector perspective, in accordance with Consolidated Health Economic Evaluation Reporting Standards. Results from this study showed that lifetime quality-adjusted life-years were 4.43 and 4.04 in the INPEFA and placebo groups, respectively. In another study, “Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure,” recently published in the Journal of Comparative Effectiveness Research, the research team used published real-world data to derive baseline event frequencies and SOLOIST-WHF study data to estimate the efficacy of INPEFA. According to the research results, the use of INPEFA led to a net gain in QALYs of 0.425 for INPEFA versus standard of care. The investigators concluded that INPEFA is a cost-effective addition to standard of care for patients hospitalized with heart failure and comorbid diabetes.